Related Experiment Video
Updated: Aug 29, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Prognostic factors of immunotherapy in metastatic renal cell carcinoma
1Clinic of Hematology & Oncology, Tartu University Clinics, Vallikraavi 7, Tartu, 51003 ESTONIA. peeter.padrik@kliinikum.ee
Abstract:
The prognosis of the majority of patients with metastatic renal cell carcinoma is poor, and there is no internationally recognized standard therapy for these patients. Patients are treated with interferon alpha or interleukin- 2 monotherapy, or combinations outside of clinical trials and a subgroup of patients responds to these therapies. Because immunotherapy induces adverse effects in almost every patient, it is necessary to avoid treating patients who will not, in the end, benefit from the treatment. It is therefore sensible to carefully select patients prior to the initiation of immunotherapy. Determining prognostic factors of survival or of rapid progression under treatment would be of help for selecting patients for immunotherapy. This article reviews current data about prognostic and predictive factors from immunotherapy studies in metastatic renal cell carcinoma comparing all analyzed factors with those that demonstrated an independent prognostic significance in multivariate analyses.
Insights
Identifying prognostic factors is crucial for selecting patients with metastatic renal cell carcinoma for immunotherapy. This helps avoid adverse effects in non-responders and improves treatment outcomes.
Area of Science:
- Oncology
- Immunotherapy
- Renal Cell Carcinoma
Background:
- Metastatic renal cell carcinoma (mRCC) has a poor prognosis with limited standard therapies.
- Current treatments involve interferon-alpha or interleukin-2, with variable response rates.
- Immunotherapy causes significant adverse effects, necessitating careful patient selection.
Purpose of the Study:
- To review prognostic and predictive factors in mRCC immunotherapy studies.
- To identify factors that predict response or progression during treatment.
- To aid in selecting patients likely to benefit from immunotherapy.
Main Methods:
- Systematic review of immunotherapy studies in mRCC.
- Analysis of prognostic and predictive factors reported in the literature.
- Comparison of factors against those with independent prognostic significance in multivariate analyses.
Main Results:
- Identified various prognostic and predictive factors from mRCC immunotherapy trials.
- Highlighted factors with demonstrated independent prognostic significance.
- Emphasized the need for validated biomarkers for patient selection.
Conclusions:
- Accurate patient selection for immunotherapy in mRCC is essential.
- Prognostic and predictive factors can guide treatment decisions.
- Further research is needed to refine patient stratification for optimal outcomes.
